Companies

Aurobindo gets tentative USFDA nod for generic Venlafaxine

PTI New Delhi | Updated on February 24, 2011 Published on February 24, 2011

Aurobindo Pharma said on Thursday that it has received tentative approval from the US health regulator to market its generic Venlafaxine capsules used for treating major depressive disorder (MDD).

In a filing to the Bombay Stock Exchange (BSE), the company said the tentative approval from the United States Food and Drug Administration (USFDA) is for multiple strengths of 37.5 mg, 75 mg and 150 mg of Venlafaxine Extended Release Capsules.

These capsules are generic equivalent of Wyeth Pharmaceuticals Inc’s Effexor XR capsules in the strengths of 37.5 mg, 75 mg and 150 mg, it added.

The company claimed that it had filed for the approval under Paragraph IV certification, which would have given it 180 days of marketing exclusivity but it is currently under litigation in the US District Court of New Jersey.

It further added that the product will be launched after the litigation settlement.

“According to IMS, the product has a market size of approximately USD 2.4 billion for the twelve months ending September 2010,” Aurobindo Pharma said.



Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on February 24, 2011
This article is closed for comments.
Please Email the Editor